Jefferies stays Buy on Supernus Pharmaceuticals (SUPN) as weekly scripts near 'historical levels'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $65.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN)The analyst commented, "Following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
